Abstract
Since the introduction of chemotherapeutic agents effective in the treatment of streptococcic and pneumococcic infections, efforts have been made to improve on these agents and to develop a compound equally effective against infections caused by staphylococci. Sulfathiazole (2-sulfanilamidothiazole) and sulfamethylthiazole (2-sulfanilamido-4-methylthiazole) have shown promise in this direction. Sulfamethylthiazole is a white amorphous powder which is less soluble than sulfanilamide, sulfapyridine or sulfathiazole. Sulfamethylthiazole (together with sulfathiazole) was first synthesized in August 1939 by Fosbinder and Walter, 1 who also reported its effectiveness against streptococci and pneumococci. Lawrence 2 found sulfathiazole and sulfamethylthiazole to be superior to sulfanilamide in their bacteriostatic effect against Lancefield group A Streptococcus haemolyticus and against the colon-typhoid-dysentery group. Barlow and Homburger 3 reported that in experimentally produced infections with Str. haemolyticus and Pneumococcus types I, II and III the effect of thiazole derivatives of sulfanilamide was definitely superior to that of the parent substance and compared
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
